These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34825941)

  • 1. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.
    Yamanishi M; Narazaki H; Asano T
    Exp Hematol; 2015 Mar; 43(3):207-14. PubMed ID: 25461250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
    J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
    Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
    Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
    [No Abstract]   [Full Text] [Related]  

  • 7. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
    Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
    Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
    PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells.
    Leegwater PA; De Abreu RA; Albertioni F
    Cancer Lett; 1998 Aug; 130(1-2):169-73. PubMed ID: 9751270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
    Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
    BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
    Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
    Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
    Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
    Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
    J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.